These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis. Jiang HY; Zhang MN; Chen HJ; Yang Y; Deng M; Ruan B Int J Infect Dis; 2014 Aug; 25():130-5. PubMed ID: 24911886 [TBL] [Abstract][Full Text] [Related]
5. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. Boulle A; Van Cutsem G; Cohen K; Hilderbrand K; Mathee S; Abrahams M; Goemaere E; Coetzee D; Maartens G JAMA; 2008 Aug; 300(5):530-9. PubMed ID: 18677025 [TBL] [Abstract][Full Text] [Related]
6. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. Bonnet M; Bhatt N; Baudin E; Silva C; Michon C; Taburet AM; Ciaffi L; Sobry A; Bastos R; Nunes E; Rouzioux C; Jani I; Calmy A; Lancet Infect Dis; 2013 Apr; 13(4):303-12. PubMed ID: 23433590 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Swaminathan S; Padmapriyadarsini C; Venkatesan P; Narendran G; Ramesh Kumar S; Iliayas S; Menon PA; Selvaraju S; Pooranagangadevi NP; Bhavani PK; Ponnuraja C; Dilip M; Ramachandran R Clin Infect Dis; 2011 Oct; 53(7):716-24. PubMed ID: 21890776 [TBL] [Abstract][Full Text] [Related]
8. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. Manosuthi W; Mankatitham W; Lueangniyomkul A; Chimsuntorn S; Sungkanuparph S HIV Med; 2008 May; 9(5):294-9. PubMed ID: 18400076 [TBL] [Abstract][Full Text] [Related]
9. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. Nachega JB; Hislop M; Dowdy DW; Gallant JE; Chaisson RE; Regensberg L; Maartens G AIDS; 2008 Oct; 22(16):2117-25. PubMed ID: 18832875 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. Bhatt NB; Barau C; Amin A; Baudin E; Meggi B; Silva C; Furlan V; Grinsztejn B; Barrail-Tran A; Bonnet M; Taburet AM; Antimicrob Agents Chemother; 2014 Jun; 58(6):3182-90. PubMed ID: 24663014 [TBL] [Abstract][Full Text] [Related]
11. Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks. Scarsi KK; Darin KM; Nakalema S; Back DJ; Byakika-Kibwika P; Else LJ; Dilly Penchala S; Buzibye A; Cohn SE; Merry C; Lamorde M Clin Infect Dis; 2016 Mar; 62(6):675-682. PubMed ID: 26646680 [TBL] [Abstract][Full Text] [Related]
12. Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study. Mwesigire DM; Wu AW; Martin F; Katamba A; Seeley J BMC Health Serv Res; 2015 Jul; 15():292. PubMed ID: 26216221 [TBL] [Abstract][Full Text] [Related]
13. Dyslipidemia among HIV-infected Patients with tuberculosis taking once-daily nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in India. Padmapriyadarsini C; Ramesh Kumar S; Terrin N; Narendran G; Menon PA; Ramachandran G; Subramanyan S; Venkatesan P; Wanke C; Swaminathan S Clin Infect Dis; 2011 Feb; 52(4):540-6. PubMed ID: 21252141 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana. Shipton LK; Wester CW; Stock S; Ndwapi N; Gaolathe T; Thior I; Avalos A; Moffat HJ; Mboya JJ; Widenfelt E; Essex M; Hughes MD; Shapiro RL Int J Tuberc Lung Dis; 2009 Mar; 13(3):360-6. PubMed ID: 19275797 [TBL] [Abstract][Full Text] [Related]
15. Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy. Padmapriyadarsini C; Bhavani PK; Tang A; Kumar H; Ponnuraja C; Narendran G; Hannah E; Ramesh C; Chandrasekar C; Wanke C; Swaminathan S Int J Infect Dis; 2013 Dec; 17(12):e1154-9. PubMed ID: 24120216 [TBL] [Abstract][Full Text] [Related]
16. The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. Cain LE; Phillips A; Lodi S; Sabin C; Bansi L; Justice A; Tate J; Logan R; Robins JM; Sterne JA; van Sighem A; de Wolf F; Bucher HC; Elzi L; Touloumi G; Vourli G; Esteve A; Casabona J; del Amo J; Moreno S; Seng R; Meyer L; Pérez-Hoyos S; Muga R; Abgrall S; Costagliola D; Hernán MA; AIDS; 2012 Aug; 26(13):1691-705. PubMed ID: 22546987 [TBL] [Abstract][Full Text] [Related]
17. Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children. Lowenthal ED; Ellenberg JH; Machine E; Sagdeo A; Boiditswe S; Steenhoff AP; Rutstein R; Anabwani G; Gross R JAMA; 2013 May; 309(17):1803-9. PubMed ID: 23632724 [TBL] [Abstract][Full Text] [Related]
18. Long-term effectiveness of first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in Ghana. Sarfo FS; Sarfo MA; Kasim A; Phillips R; Booth M; Chadwick D J Antimicrob Chemother; 2014 Jan; 69(1):254-61. PubMed ID: 24003181 [TBL] [Abstract][Full Text] [Related]
19. Influence of ABCB-1 C3435T polymorphisms on plasma nevirapine and efavirenz levels and their effects on virologic and immunological outcomes in HIV/TB co-infected Thai adults under anti-retroviral therapy. Uttayamakul S; Likanonsakul S; Manosuthi W; Wichukchinda N; Shioda T; Khusmith S Southeast Asian J Trop Med Public Health; 2012 Jan; 43(1):78-88. PubMed ID: 23082557 [TBL] [Abstract][Full Text] [Related]
20. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. Grinsztejn B; De Castro N; Arnold V; Veloso VG; Morgado M; Pilotto JH; Brites C; Madruga JV; Barcellos NT; Santos BR; Vorsatz C; Fagard C; Santini-Oliveira M; Patey O; Delaugerre C; Chêne G; Molina JM; Lancet Infect Dis; 2014 Jun; 14(6):459-67. PubMed ID: 24726095 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]